Related Experiment Video
Updated: Dec 27, 2025
Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Published on: July 6, 2013
Scientific and Regulatory Considerations for Efficacy Studies of Cytomegalovirus Vaccines
Philip R Krause1, Jeff Roberts1
1US Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Silver Spring, Maryland, USA.
Abstract:
The considerable public health burden due to cytomegalovirus (CMV) supports current interest in vaccine development. Clinical studies intended to support regulatory action should be designed to demonstrate substantial evidence of effectiveness. However, design and conduct of clinical endpoint studies may be hampered by low incidence of disease, especially for congenital CMV. Discussion and experience from other vaccines directed against congenital disease (including rubella and Zika) may be instructive. This article summarizes current scientific and US regulatory considerations related to design of studies of vaccines intended to prevent congenital CMV and complications of CMV in transplantation, as discussed at the 2018 workshop entitled "Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment."
Insights
Developing vaccines against cytomegalovirus (CMV) is crucial due to its public health impact. Designing clinical trials for congenital CMV vaccines requires careful consideration of disease incidence and regulatory standards.
Area of Science:
- Virology
- Vaccinology
- Public Health
Background:
- Cytomegalovirus (CMV) presents a significant public health challenge, driving vaccine development efforts.
- Congenital CMV infections and CMV complications in transplantation are key areas of concern.
- Low disease incidence complicates the design of clinical endpoint studies for vaccines.
Purpose of the Study:
- To summarize scientific and US regulatory considerations for designing clinical studies of vaccines targeting congenital CMV.
- To discuss strategies for evaluating CMV vaccines for preventing complications in transplantation.
- To leverage insights from vaccines against other congenital diseases.
Main Methods:
- Review of current scientific knowledge on CMV.
- Analysis of US regulatory requirements for vaccine approval.
- Discussion of experiences with vaccines for rubella and Zika virus.
Main Results:
- Identified challenges in designing CMV vaccine trials due to low disease incidence.
- Highlighted the importance of substantial evidence of effectiveness for regulatory approval.
- Emphasized the need for tailored study designs based on disease context (congenital vs. transplantation).
Conclusions:
- Designing effective clinical trials for CMV vaccines, particularly for congenital infections, requires innovative approaches.
- Regulatory pathways must accommodate the unique challenges of studying vaccines for rare or difficult-to-measure endpoints.
- Further discussion and collaboration are needed to advance CMV vaccine development strategies.
